NIVF Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -- compared to NewGenIvf Group's net margin of 21.81%. NewGenIvf Group's return on equity of -- beat BioNTech SE's return on equity of -3.39%.

NewGenIvf Group has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $140.40 which suggests that it could grow by 37.68%. Given that BioNTech SE has higher upside potential than NewGenIvf Group, analysts believe BioNTech SE is more attractive than NewGenIvf Group.

NewGenIvf Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.

NewGenIvf Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIvf Group pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

NewGenIvf Group quarterly revenues are --, which are smaller than BioNTech SE quarterly revenues of $1.3B. NewGenIvf Group's net income of -- is lower than BioNTech SE's net income of $276.6M. Notably, NewGenIvf Group's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIvf Group is -- versus 8.24x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Bumrungrad Hospital PCL has a net margin of -- compared to NewGenIvf Group's net margin of 28.23%. NewGenIvf Group's return on equity of -- beat Bumrungrad Hospital PCL's return on equity of 27.72%.

NewGenIvf Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Bumrungrad Hospital PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that NewGenIvf Group has higher upside potential than Bumrungrad Hospital PCL, analysts believe NewGenIvf Group is more attractive than Bumrungrad Hospital PCL.

NewGenIvf Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bumrungrad Hospital PCL has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NewGenIvf Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bumrungrad Hospital PCL offers a yield of 1.86% to investors and pays a quarterly dividend of $0.09 per share. NewGenIvf Group pays -- of its earnings as a dividend. Bumrungrad Hospital PCL pays out 52.75% of its earnings as a dividend. Bumrungrad Hospital PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

NewGenIvf Group quarterly revenues are --, which are smaller than Bumrungrad Hospital PCL quarterly revenues of $180.8M. NewGenIvf Group's net income of -- is lower than Bumrungrad Hospital PCL's net income of $51M. Notably, NewGenIvf Group's price-to-earnings ratio is -- while Bumrungrad Hospital PCL's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIvf Group is -- versus 9.44x for Bumrungrad Hospital PCL. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of -- compared to NewGenIvf Group's net margin of 16.9%. NewGenIvf Group's return on equity of -- beat Corcept Therapeutics's return on equity of 23.78%.

NewGenIvf Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 99.76%. Given that Corcept Therapeutics has higher upside potential than NewGenIvf Group, analysts believe Corcept Therapeutics is more attractive than NewGenIvf Group.

NewGenIvf Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

NewGenIvf Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIvf Group pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

NewGenIvf Group quarterly revenues are --, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. NewGenIvf Group's net income of -- is lower than Corcept Therapeutics's net income of $30.7M. Notably, NewGenIvf Group's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 57.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIvf Group is -- versus 12.06x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -- compared to NewGenIvf Group's net margin of -91.76%. NewGenIvf Group's return on equity of -- beat Novavax's return on equity of --.

NewGenIvf Group has a consensus price target of --, signalling downside risk potential of --. On the other hand Novavax has an analysts' consensus of $15.17 which suggests that it could grow by 127.39%. Given that Novavax has higher upside potential than NewGenIvf Group, analysts believe Novavax is more attractive than NewGenIvf Group.

NewGenIvf Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

NewGenIvf Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIvf Group pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

NewGenIvf Group quarterly revenues are --, which are smaller than Novavax quarterly revenues of $88.3M. NewGenIvf Group's net income of -- is lower than Novavax's net income of -$81M. Notably, NewGenIvf Group's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIvf Group is -- versus 1.53x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.